Perspective

iMedPub Journals
www.imedpub.com

Journal of Stroke Research & Therapy

2025
Vol.9 No.2:235

Inflammatory Mechanisms and Neuroinflammation Pathways in Stroke Pathology

Yanrong Zheng*

Department of Neurosurgery, Soochow University, Suzhou, China

***Corresponding author:** Yanrong Zheng, Department of Neurosurgery, Soochow University, Suzhou, China; E-mail: zheng@gmail.com

Received date: December 10, 2024, Manuscript No. IPSRT-24-20093; **Editor assigned date:** December 13, 2024, PreQC No. IPSRT-24-20093 (PQ); **Reviewed date:** December 28, 2024, QC No. IPSRT-24-20093; **Revised date:** June 10, 2025, Manuscript No. IPSRT-24-20093 (R); **Published date:** June 18, 2025, DOI: 10.36648/ipsrt.9.2.235

Citation: Zheng Y (2025) Inflammatory Mechanisms and Neuroinflammation Pathways in Stroke Pathology. Stroke Res Ther Vol:9 No:2

Description

Neuroinflammation plays a critical role in the pathophysiology of stroke, encompassing both ischemic and hemorrhagic forms. Strokes, caused either by a blockage in cerebral blood flow or the rupture of a blood vessel, trigger a cascade of cellular and molecular events that result in neuronal injury. This process is heavily influenced by the activation of neuroinflammatory pathways, which mediate both protective and detrimental effects. Understanding these pathways is crucial for developing targeted therapeutic interventions to mitigate the damage and enhance recovery. In ischemic stroke, the interruption of blood flow deprives brain tissue of oxygen and nutrients, leading to energy failure and cell death. Within minutes, the hypoxic environment triggers the release of Damage-Associated Molecular Patterns (DAMPs), such as High-Mobility Group Box 1 (HMGB1) and heat-shock proteins. These molecules activate Pattern Recognition Receptors (PRRs), including Toll-Like Receptors (TLRs) and Nucleotide-binding Oligomerization Domain (NOD)-like receptors on microglia and astrocytes. This activation initiates a pro-inflammatory response, resulting in the release of cytokines like Interleukin-1β (IL-1β), Tumor Necrosis Factor-Alpha (TNF-α), and chemokines that recruit peripheral immune cells. The innate immune response also involves the assembly of the inflammasome, a multiprotein complex that amplifies the release of IL-1β and IL-18, exacerbating the inflammatory cascade. The Blood-Brain Barrier (BBB), a vital structure for maintaining cerebral homeostasis, becomes compromised due to Matrix Metalloproteinases (MMPs) released by activated immune cells. This permeability allows neutrophils, monocytes, and T-cells to infiltrate the brain, further amplifying inflammation and causing secondary neuronal damage. Hemorrhagic stroke, characterized by bleeding within the brain parenchyma or subarachnoid space, induces inflammation through different mechanisms. The extravasation of blood into the brain triggers the release of hemoglobin and its degradation products, such as heme and iron, which are highly toxic. These products activate microglia and astrocytes, initiating an inflammatory response. The recruitment of neutrophils and macrophages to the site of injury results in the production of Reactive Oxygen Species (ROS) and pro-inflammatory cytokines, which can worsen the oxidative stress and neuronal damage.

The role of peripheral immune cells

Peripheral immune cells, including neutrophils, monocytes, and T cells, contribute significantly to post-stroke inflammation. Neutrophils are among the first responders, releasing proteases like neutrophil elastase that degrade the BBB and amplify tissue damage. Monocytes and macrophages infiltrate the brain, where they differentiate into pro-inflammatory or anti-inflammatory subtypes depending on the microenvironment. Regulatory T cells (Tregs) exert protective effects by suppressing excessive inflammation, while cytotoxic T cells can contribute to neuronal apoptosis. The spleen, a reservoir of immune cells, undergoes rapid atrophy following stroke, releasing a surge of monocytes and neutrophils into circulation. This systemic immune response further influences neuroinflammation and underscores the interconnectedness of the CNS and peripheral immune systems. Cytokines and chemokines are pivotal mediators of neuroinflammation in stroke. Pro-inflammatory cytokines, such as IL-1β and TNF-α, promote the activation of glial cells and the recruitment of peripheral immune cells. Chemokines like C-C motif chemokine ligand 2 (CCL2) and C-X-C Motif Chemokine Ligand 1 (CXCL1) facilitate the migration of monocytes and neutrophils to the site of injury. Conversely, anti-inflammatory cytokines, including IL-10 and TGF-β, are critical for resolving inflammation and promoting tissue repair. The balance between pro- and anti-inflammatory signals determines the extent of neuronal damage and the potential for recovery. Dysregulation of this balance, often observed in severe strokes, leads to prolonged inflammation and poor outcomes.

The role of reactive oxygen species

ROS are generated in large quantities during stroke due to mitochondrial dysfunction and the activation of NADPH oxidase in immune cells. While ROS play a role in signaling pathways that mediate repair, excessive production leads to oxidative stress, damaging lipids, proteins, and DNA. This oxidative damage exacerbates BBB disruption and activates additional inflammatory pathways, creating a vicious cycle of injury. Antioxidant systems, such as Superoxide Dismutase (SOD) and glutathione peroxidase, are often overwhelmed during stroke, highlighting the potential benefit of therapies aimed at enhancing endogenous antioxidant defenses. Targeting neuroinflammatory pathways offers a promising avenue for

stroke therapy. Preclinical studies have explored the use of anti-inflammatory agents, such as IL-1 receptor antagonists and inhibitors of MMPs, to reduce BBB permeability and neuronal injury. Immunomodulatory strategies, including the use of Treg-boosting agents and microglial phenotype modulators, are under investigation for their potential to enhance neuroprotection and recovery. Stem cell therapies, which can suppress inflammation and promote neural regeneration, represent another emerging approach. Mesenchymal Stem Cells (MSCs), in particular, have shown promise in reducing infarct size and improving functional outcomes in animal models of stroke. The timing and specificity of anti-inflammatory interventions are critical; as indiscriminate suppression of inflammation may hinder repair processes. Precision medicine approaches that consider individual variations in immune responses and genetic predispositions are likely to enhance the efficacy of such therapies.